CSL +1.67% leads healthcare surge — defensive rotation has institutional momentum
CSL Limited advanced +1.67% to $335.24, the session's standout performer, confirming that the healthcare rotation running in recent weeks has superannuation fund support behind it. Motley Fool Australia noted Sunday that CSL had fallen -5% after a strong rally — but Sunday's firm recovery print rebuffed the correction narrative decisively. CSL's improving operational outlook, driven by plasma collection recovery and immunology pipeline progress, justifies its premium valuation for quality-mandate holders. The pattern is characteristic of end-of-quarter defensive accumulation: smooth price action, broad healthcare sector participation, no single drug-trial catalyst — consistent with managed fund rebalancing into the highest-quality large-cap healthcare name on the ASX.
Read at Motley Fool Australia ↗